Do driver mutations influence treatment outcomes in myelofibrosis?
The absence of cancer-related mutations 30 days after a transplant in patients with myelofibrosis might be more effective in measuring treatment response than
Myeloproliferative Neoplasms
Primary Myelofibrosis
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
Researchers call for ‘evidence-based’ driving restrictions for patients treated with CAR-T therapy
Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration.
Leukemia
Pathways & Perspectives with Pia Raanani, MD
Pathways & Perspectives Meet Pia Raanani, MD, head of the Institute of Hematology at the Davidoff Cancer Center, Rabin Medical Center in Israel
Acute Myeloid Leukemia
Leukemia
Myelodysplastic Syndromes
NCI’s myeloMATCH precision medicine initiative pushes the envelope in myeloid leukemia care
A new National Cancer Institute (NCI) initiative seeks to redefine the standard for personalized cancer care in acute myeloid leukemia (AML) and myelodysplastic
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Aspiring hem/onc fellows discuss myeloma research, SOHO Annual Meeting opportunities
Wajeeha Aiman, MD, and Muhammad Ashar Ali, MD, discuss the benefits of attending the SOHO Annual Meeting in Houston, Texas, for early-career healthcare
66th American Society of Hematology Annual Meeting & Exposition
Meetings / Conferences
Zamto-cel shows promise in interim results from phase 2 pivotal study
In the video interview, Overstijns and Dr. Wijatyk discuss interim results from the phase 2 pivotal Study (DALY II USA) evaluating zamtocabtagene autoleucel
66th American Society of Hematology Annual Meeting & Exposition
Meetings / Conferences
Novel CAR-T therapy targets calreticulin-mutant myeloproliferative neoplasms
The novel CAR-T demonstrated robust and highly selective eradication of low- and high- mutCALR expressing human cell lines in vitro.
66th American Society of Hematology Annual Meeting & Exposition
MDS
Meetings / Conferences
Society Updates
SOHO president looks back on 2024
For SOHO, 2024 was a year of firsts and continued growth of the society worldwide.
Society Updates
Member Spotlight: Phillip Scheinberg, MD, PhD | 2024-2025 SOHO President
The Board of Directors and the Steering Committee of the Society of Hematologic Oncology (SOHO) are pleased to announce that Phillip Scheinberg, MD,
66th American Society of Hematology Annual Meeting & Exposition
Leukemia
Meetings / Conferences
Trem-cel enables repeated post-HCT maintenance dosing of gemtuzumab ozogamicin in patients with high-risk AML
Trem-cel enables repeated post-HCT maintenance dosing of gemtuzumab ozogamicin in patients with high-risk AML.